ADMA BiologicsADMA
ADMA logo
Fair Value
US$20.93
Share price11 Nov
US$8.9557.2% undervalued intrinsic discount
Loading
1Y-51.04%
7D2.29%

Valuation analysis

Author hasn't set their bio yet

Published
12 Aug 24
Updated
11 Nov 24
Views
349
Invested

Fair Value vs Share Price

US$20.93
vs US$8.9557.2% undervalued intrinsic discount
PastFuture-74m1b20132016201920222024202520282029Revenue US$1.0bEarnings US$314.6m
26%
Revenue growth
30%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on ADMA Biologics

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and undervalued.

Market capUS$2.1b
PB5.3x
Estimated Growth14.6%
Dividend YieldN/A
Full analysis

CEO & management

Adam Grossman
CEO
1.9yrs
CEO Tenure

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.